Compare CNX & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNX | BLTE |
|---|---|---|
| Founded | 1860 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 6.6B |
| IPO Year | 1998 | 2021 |
| Metric | CNX | BLTE |
|---|---|---|
| Price | $38.29 | $155.01 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $35.71 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 1.7M | 98.2K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 763.33 | N/A |
| EPS | ★ 2.18 | N/A |
| Revenue | ★ $2,239,134,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.14 | $492.11 |
| P/E Ratio | $17.52 | ★ N/A |
| Revenue Growth | ★ 76.76 | N/A |
| 52 Week Low | $27.72 | $56.68 |
| 52 Week High | $43.62 | $200.00 |
| Indicator | CNX | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 42.67 | 40.61 |
| Support Level | $37.42 | $148.06 |
| Resistance Level | $38.28 | $161.28 |
| Average True Range (ATR) | 1.01 | 6.20 |
| MACD | -0.01 | -1.18 |
| Stochastic Oscillator | 21.28 | 3.36 |
CNX Resources Corp is an independent natural gas development, production, midstream and technology company centered in the Appalachian Basin. It is focused on unconventional shale formations, prominently the Marcellus Shale and Utica Shale, in Pennsylvania, Ohio and West Virginia. Additionally, the company operates and develops Coalbed Methane (CBM) properties in Virginia. the company has two reportable segments: Shale and Coalbed Methane. The majority of the company's revenue is derived from the Shale segment.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.